ATXS

Astria Therapeutics Inc

Add to Watchlist

Advanced Chart

6.650

+0.09(1.372%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.755

Open

6.550

VWAP

6.57

Vol

117.14K

Mkt Cap

375.29M

Low

6.420

Amount

769.52K

EV/EBITDA(TTM)

Total Shares

54.91M

170.47M

EV/OCF(TTM)

P/S(TTM)

Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

7 Analyst Rating

340.45% Upside

Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is 29.29 USD with a low forecast of 16.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

340.45% Upside

Current: 6.650

Low

16.00

Averages

29.29

High

47.00

340.45% Upside

Current: 6.650

Low

16.00

Averages

29.29

High

47.00

Citizens JMP

Outperform

NULL

downgrade

$26 -> $25

2025-05-14

Reason

Citizens JMP

Price Target

$26 -> $25

2025-05-14

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Astria Therapeutics to $25 from $26 and keeps an Outperform rating on the shares. Data for navenibart expected mid-year could bolster confidence in Astria's extended dosing intervals with the first clinical data for STAR-0310 following in Q3, the analyst tells investors in a research note. Astria is executing well on its Phase 3 ALPHA-ORBIT trial of navenibart, and Citizens continues to like navenibart's positioning within the hereditary angioedema pipeline.

Wedbush

Laura Chico

Buy

Maintains

$27 → $28

2025-03-12

Reason

Wedbush

Laura Chico

Price Target

$27 → $28

2025-03-12

Maintains

Buy

Reason

Wedbush raised the firm's price target on Astria Therapeutics to $28 from $27 and keeps an Outperform rating on the shares. The firm says that all development timelines remain on track for lead program navenibart in HAE, with the Phase 3 ALPHA-ORBIT study underway and incorporating two regimens. Potential top-line results remain on track for early 2027. Given the parallels between Takhzyro and navenibart, Wedbush anticipates strong patient interest in the study.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2025-03-11

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-03-11

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Jonathan Wolleben

Buy

Reiterates

$26

2025-03-03

Reason

Citizens Capital Markets

Jonathan Wolleben

Price Target

$26

2025-03-03

Reiterates

Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2025-02-27

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-02-27

Reiterates

Strong Buy

Reason

JMP Securities

Jonathan Wolleben

Buy

Initiates

$26

2025-01-31

Reason

JMP Securities

Jonathan Wolleben

Price Target

$26

2025-01-31

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Astria Therapeutics Inc (ATXS.O) is -2.75, compared to its 5-year average forward P/E of -3.90. For a more detailed relative valuation and DCF analysis to assess Astria Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.90

Current PE

-2.75

Overvalued PE

-1.73

Undervalued PE

-6.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.65

Current EV/EBITDA

-1.11

Overvalued EV/EBITDA

-0.03

Undervalued EV/EBITDA

-3.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00